RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines
Aug 24, 2020•almost 5 years ago
Amount Raised
$2 Million
Round Type
seed
Description
RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announces today completion of its $2.35 million seed round financing from multiple venture capitalists including Terra Magnum Capital Partners. The Company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.
FundzWatch™ Score
62
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood